Evidence map›Paper›PMID 34504309›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2022

Identification of novel SSX1 fusions in synovial sarcoma.

Akihiko Yoshida, Yasuhito Arai, Kaishi Satomi, Takashi Kubo, Eijitsu Ryo, Yuko Matsushita, Natsuko Hama, Kazuki Sudo, Motokiyo Komiyama, Yasushi Yatabe and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Synovial Sarcoma: Molecular Biology, Pathology, and Therapeutic Strategies.International journal of molecular sciences · 2026
    Review
  3. Article
  4. BAF complex-independent gene activation by SS18::SSX.bioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Molecular Profiling ofJournal of personalized medicine · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. The Recent Advances in Molecular Diagnosis of Soft Tissue Tumors.International journal of molecular sciences · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Akihiko YoshidaDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan. akyoshid@ncc.go.jp.ORCID http://orcid.org/0000-0002-3373-0099
Yasuhito AraiDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0001-6306-9409
Kaishi SatomiDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0001-7611-5822
Takashi KuboDepartment of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan.
Eijitsu RyoDivision of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan.
Yuko MatsushitaDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.
Natsuko HamaDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Kazuki SudoRare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.
Motokiyo KomiyamaRare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.
Yasushi YatabeDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0003-1788-559X
Tatsuhiro ShibataDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Hitoshi IchikawaDepartment of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0003-0142-2240
Koichi IchimuraDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3851-2349
Akira KawaiRare Cancer Center, National Cancer Center Hospital, Tokyo, Japan.
Taisuke MoriDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0003-1838-7883
Tokyo National Hospital · JPJuntendo University · JPNational Cancer Center · USNational Cancer Center Hospital East · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synovial sarcoma is characterized by variable epithelial differentiation and specific SS18-SSX gene fusions. The diagnosis is primarily based on phenotype, but fusion gene detection is increasingly being considered indispensable, with SS18 break-apart fluorescence in situ hybridization (FISH) being favored in many laboratories. However, SS18 FISH assay produces negative or atypical results in a minority of cases, leaving uncertainties in diagnosis and management. Here, we analyzed this challenging subset of SS18 FISH-negative/atypical synovial sarcoma using RNA sequencing and monoclonal antibodies that recognize SS18-SSX and the SSX C-terminus. Among 99 synovial sarcoma cases that were previously subjected to SS18 break-apart FISH, eight cases were reported as negative and three cases were indeterminate, owing to atypical signal patterns. Three of these 11 tumors (two monophasic and one biphasic) harbored novel EWSR1-SSX1 fusions, were negative for SS18-SSX staining, and were positive for SSX C-terminus staining. One monophasic tumor harbored a novel MN1-SSX1 fusion, and showed negative SS18-SSX expression and positive SSX C-terminus staining. Another monophasic tumor carried an SS18L1-SSX1 fusion, and was weakly positive for SS18-SSX, while SMARCB1 expression was reduced. The presence of these novel and/or rare fusions was confirmed using RT-PCR and Sanger sequencing. EWSR1-SSX1 was further validated by EWSR1 FISH assay. The remaining six tumors (five monophasic and one biphasic) showed strong SS18-SSX expression, and RNA sequencing successfully performed in three cases identified canonical SS18-SSX2 fusions. Based on a DNA methylation-based unsupervised clustering, the tumors with EWSR1-SSX1 and SS18L1-SSX1 clustered with synovial sarcoma, while the MN1-SSX1-positive tumor was not co-clustered despite classic histology and immunoprofile. In summary, we discovered novel and rare SSX1 fusions to non-SS18 genes in synovial sarcoma. The expanded genetic landscape carries significant diagnostic implications and advances our understanding of the oncogenic mechanism.

Indexed as

Sarcoma, SynovialHumansIn Situ Hybridization, FluorescenceOncogene Proteins, FusionProto-Oncogene ProteinsRepressor ProteinsOncogene Proteins, FusionProto-Oncogene ProteinsRepressor Proteins

Identifiers

PMID34504309
OpenAlexW3196631354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.